1,2-Dioxaspiro<4.4>nonan | 41561-18-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氧戊环
• 英文名称: 1,2-Dioxaspiro<4.4>nonan
• 英文别名: Dioxaspiro[4.4]nonane；1,2-dioxaspiro[4.4]nonane
• CAS: 41561-18-6
• 化学式: C₇H₁₂O₂
• 分子量: 128.171
• InChiKey: ZURBCJWBZRZMHO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  亚甲基环戊烷 、 二螺[2.1.2.2]壬烷,4-亚甲基- 在 臭氧 作用下， 生成 1,2-Dioxaspiro<4.4>nonan
  参考文献：
  名称：

  Reiser, Ralf; Sueling, Carsten; Schroeder, Gerhard, Chemische Berichte, 1992, vol. 125, # 11, p. 2493 - 2502

  摘要：

  DOI：

文献信息

• [EN] PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF<br/>[FR] COMPOSÉS CONTENANT DE LA PIPÉRIDINE ET LEURS UTILISATIONS
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2010080864A1

  公开（公告）日：2010-07-15

  A method for preventing and/or treating a metabolic disease, cerebrovascular disease, etc. which comprises administering to a mammal an effective amount of the compound of the formula (I) wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof. And a novel compound of the formula (I-1): wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof has an anti-diabetic effect and a neuroprotective effect. Accordingly, the compound of the formula (I) and the compound of the formula (I-1) are useful in a method for preventing and/or treating for a metabolic disease such as diabetes, cerebrovascular disease such as stroke, etc.

  一种预防和/或治疗代谢性疾病、脑血管疾病等的方法，包括向哺乳动物施用化合物的有效量，其化学式为(I)，其中所有符号的含义与规范中定义的相同；其盐、N-氧化物、溶剂合物或前药。以及化学式(I-1)的新化合物：其中所有符号的含义与规范中定义的相同；其盐、N-氧化物、溶剂合物或前药具有抗糖尿病作用和神经保护作用。因此，化合物(I)和化合物(I-1)在预防和/或治疗代谢性疾病如糖尿病、脑血管疾病如中风等方面是有用的。
• NITRILES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1724264A1

  公开（公告）日：2006-11-22

  The present invention relates to a compound of formula (I) wherein Y and Z each is independently N or C; ring A is a carbocyclic group or a heterocyclic group; ring B is a heterocyclic group containing at least one nitrogen atom; R is a hydrogen atom, a substituent, etc,; n is 0, or an integer of from 1 to 10, a salt thereof, a solvate thereof, or an N-oxide thereof, or a prodrug thereof. The compound of formula (I), a salt thereof, a solvate thereof, or an N-oxide thereof, or a prodrug thereof has an inhibitory activity against cysteine protease, and it is useful for the prophylaxis and/or treatment of a cysteine protease-related disease such as osteoporosis, etc.

  本发明涉及一种具有以下式（I）的化合物，其中Y和Z各自独立地为N或C；环A为碳环基团或杂环基团；环B为含有至少一个氮原子的杂环基团；R为氢原子、取代基等；n为0，或为1至10的整数，其盐、溶剂合物、N-氧化物或前药。具有式（I）的化合物，其盐、溶剂合物、N-氧化物或前药对半胱氨酸蛋白酶具有抑制活性，对于预防和/或治疗半胱氨酸蛋白酶相关疾病如骨质疏松症等是有用的。
• Nitrogenous heterocyclic compounds and medical use thereof
  申请人：Takahashi Kanji

  公开号：US20070010529A1

  公开（公告）日：2007-01-11

  The present invention relates to a compound represented by formula (I): (wherein all the symbols have the same meanings as defined in the above description) and a production method and use thereof. The compounds represented by formula (I), or its salt, N-oxide or solvate, or a prodrug thereof have p38 MAP kinase inhibitory activity, and are useful in the prevention and/or treatment of those diseases that are supposedly caused or deteriorated by abnormal production of cytokines including inflammatory cytokine or chemokine, or by over response thereto, namely cytokine-mediated diseases such as inflammatory diseases, respiratory diseases, cardiovascular disease, central nervous system diseases, and the like.

  本发明涉及一种由以下式表示的化合物：(其中所有符号的含义与上述描述中定义的相同)，以及其生产方法和用途。由式(I)表示的化合物，或其盐、N-氧化物或溶剂合物，或其前药，在p38 MAP激酶抑制活性方面具有作用，并且在预防和/或治疗那些据称由细胞因子异常产生或恶化引起，或由过度反应引起的疾病方面有用，即细胞因子介导的疾病，如炎症性疾病、呼吸系统疾病、心血管疾病、中枢神经系统疾病等。
• NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1741702A1

  公开（公告）日：2007-01-10

  The present invention provides a compound having p38 MAP kinase inhibitory activity. Because of having p38 MAP kinase inhibitory activity, the compounds represented by the formula (I): wherein each symbol is as defined in the description, salts thereof, N-oxides thereof, solvates thereof, or prodrugs thereof are useful in preventing and/or treating diseases that are supposedly caused or deteriorated by abnormal production of cytokines including inflammatory cytokines or chemokines, or by overresponse thereto, namely cytokine-mediated diseases such as inflammatory diseases, respiratory diseases, cardiovascular diseases and bone diseases.

  本发明提供了一种具有p38 MAP激酶抑制活性的化合物。由于具有p38 MAP激酶抑制活性，由式(I)所表示的化合物：其中每个符号如描述中所定义，其盐、N-氧化物、溶剂合物或前药在预防和/或治疗据称由细胞因子异常产生或恶化引起的疾病方面具有用处，包括炎症性细胞因子或趋化因子，或由对其过度反应引起的疾病，即细胞因子介导的疾病，如炎症性疾病、呼吸系统疾病、心血管疾病和骨疾病。
• HETEROCYCLIC SPIRO COMPOUND
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1683797A1

  公开（公告）日：2006-07-26

  The compound represented by formula (I) (wherein D and G are cyclic group which may have a substituent(s) or alkyl which may have a substituent(s), W and Y are a bond or a spacer of which main chain has an atom number of 1-4, ringA and ringB are heterocyclic ring which may have a substituent(s), containing at least one carbon atom and one nitrogen atom and the ringA and ringB share one spiro carbon atom.), a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug thereof Since the compounds represented by formula (I), a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug thereof have the affinity to MBR, they are useful for the prevention and/or treatment for disease caused by stress.

  公式（I）所代表的化合物（其中D和G是可能具有取代基的环族，或者是可能具有取代基的烷基，W和Y是具有1-4个原子编号的主链的键或间隔物，环A和环B是可能具有取代基的杂环，含有至少一个碳原子和一个氮原子，环A和环B共享一个螺环碳原子），其盐，N-氧化物或溶剂合物，或其前药。由于公式（I）所代表的化合物，其盐，N-氧化物或溶剂合物，或其前药对MBR具有亲和力，因此它们对于预防和/或治疗由压力引起的疾病是有用的。